![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real World Experience with DAA Regimens - Phase 4 HCV TARGET Study
|
|
|
- Phase 4 Study: Sofosbuvir+Peg/Rbv, Sofosbuvir+Rbv, Simeprevir+sofosbuvir, Simeprevir+sofosbuvir+Rbv
Reported by Jules Levin
AASLD/EASL Special Conference on Hepatitis C
New York City, New York
September 12 - 13
David R Nelson MD
Assistant Vice President for Research
Professor of Medicine
Director, Clinical and Translational Science Institute
University of Florida
Gainesville, USA
![ICAAC1.gif](../images/091514/091514-6/ICAAC1.gif)
![ICAAC2.gif](../images/091514/091514-6/ICAAC2.gif)
![ICAAC3.gif](../images/091514/091514-6/ICAAC3.gif)
![ICAAC4.gif](../images/091514/091514-6/ICAAC4.gif)
![ICAAC5.gif](../images/091514/091514-6/ICAAC5.gif)
![ICAAC6.gif](../images/091514/091514-6/ICAAC6.gif)
![ICAAC7.gif](../images/091514/091514-6/ICAAC7.gif)
![ICAAC8.gif](../images/091514/091514-6/ICAAC8.gif)
![ICAAC9.gif](../images/091514/091514-6/ICAAC9.gif)
![ICAAC10.gif](../images/091514/091514-6/ICAAC10.gif)
![ICAAC11.gif](../images/091514/091514-6/ICAAC11.gif)
![ICAAC12.gif](../images/091514/091514-6/ICAAC12.gif)
![ICAAC13.gif](../images/091514/091514-6/ICAAC13.gif)
![ICAAC14.gif](../images/091514/091514-6/ICAAC14.gif)
![ICAAC15.gif](../images/091514/091514-6/ICAAC15.gif)
![ICAAC16.gif](../images/091514/091514-6/ICAAC16.gif)
![ICAAC17.gif](../images/091514/091514-6/ICAAC17.gif)
![ICAAC18.gif](../images/091514/091514-6/ICAAC18.gif)
![ICAAC19.gif](../images/091514/091514-6/ICAAC19.gif)
![ICAAC20.gif](../images/091514/091514-6/ICAAC20.gif)
![ICAAC21.gif](../images/091514/091514-6/ICAAC21.gif)
![ICAAC22.gif](../images/091514/091514-6/ICAAC22.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|